Phathom Pharmaceuticals Upgraded by Barclays, Analysts Predict 116.48% Upside

Barclays upgraded Phathom Pharmaceuticals (PHAT) to Overweight from Equal-Weight, with an average one-year price target of $23.36/share, a 116.48% increase from its latest closing price of $10.79/share. The projected annual revenue is 460MM, up 162.63%, and the projected annual non-GAAP EPS is -4.78. The fund sentiment shows 190 funds reporting positions in PHAT, with an average portfolio weight of 0.31%.